ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

recombinant human thrombopoietin

Also written as “Recombinant human thrombopoietin”, “rhTPO” and “Recombinant human thrombopoietin for injection (rhTPO)”.

Its studies are mostly in Thrombocytopenia · Liver Cirrhosis, led by 2 companies.

Drug pageRecombinant human thrombopoietin: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 31, 20214 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio30 open or runningphase 1since Dec 31, 2021Aug 15, 2018none ahead
MIBIO PTE.its history only11 open or runningphase 3since Oct 28, 2026Oct 28, 2026Oct 31, 2028phase 3 · NCT07911800

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of 3SBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2018First study: early phase 1 study in Liver CirrhosisFirst studyNCT03673215 · 58 enrolled · China
  2. Dec 31, 2021Phase 1 study in ThrombocytopeniaNCT05193201 · 54 enrolled · China
  3. Oct 4, 2024Phase 1 study in Healthy SubjectsNCT06630494 · 22 enrolled · Australia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 3SBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06630494Healthy Subjects · Australia1CompletedNov 18, 202422
NCT05193201Thrombocytopenia · China1UNKNOWNOct 16, 202254
NCT03673215Liver Cirrhosis · ChinaEarly 1UNKNOWNOct 8, 202058

How it is read

Names in the registry

  • “Recombinant human thrombopoietin”, 4 entries
  • “rhTPO”, 1 entry
  • “Recombinant human thrombopoietin for injection (rhTPO)”, 1 entry
  • “recombinant human thrombopoietin injection”, 1 entry
  • “recombinant human thrombopoietin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.